Skip to main content

Table 1 Frequency of Tregs in situ (lesions biopsy), ex vivo (peripheral blood), and in in vitro stimulated PBMC, and CTLA-4 expression by the Tregs, in the transplant recipient as compared with the T1R group

From: Severe type 1 upgrading leprosy reaction in a renal transplant recipient: a paradoxical manifestation associated with deficiency of antigen-specific regulatory T-cells?

  In situ (biopsy) cells/mm2 Ex vivo (PB) % In vitro (expansion) %
  Treg Trega CTLA-4b Trega CTLA-4b
     Medium ML PHA Medium ML PHA
At diagnosis 71 - - - - - - - -
Severe reaction 55 0.8 4.1 0.03 0.93 3.0 0.0 0.3 33.6
Remission
(4 months)
- 1.2 6.0 1.0 1.72 15.5 0.2 0.9 44.5
Remission
(2 years)
- 2.35 - 2.0 2.65 22.8 - - -
T1R groupc 170 ± 23 3.4 ± 0.4 24.9 ± 4.8 2.3 ± 0.3 6.9 ± 0.7 18.9 ± 1.4 13.8 ± 3.6 17.8 ± 4.7 72 ± 5.9
  1. PB peripheral blood, PBMC peripheral blood mononuclear cells, Treg regulatory T-cells, ML Mycobacterium leprae antigen, PHA phytohemaglutinnin, T1R type 1 upgrading leprosy reaction
  2. aPercentage of FoxP3+CD127low/− among CD4+CD25+ cells
  3. bPercentage of CTLA-4+ cells among Tregs
  4. cPatients with severe T1R without immunosuppressors (n = 14). Results presented as mean ± SEM